Project Grant R44CA287615
Award Date
9/20/24
Completion Date
8/31/26
Dollars Obligated
$838K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Belmont, CA, USA
Similar Awards
This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,789 to Ergami Endoscopy, Inc. to develop an automated robotic flexible overtube device capable of blind insertion during colonoscopy procedures. The device aims to reduce physician injuries, improve productivity, and decrease patient pain/sedation requirements for the over 16 million colonoscopies performed annually in the U.S. Key...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), will support the development and clinical validation of an Optical Coherence Tomography (OCT) system and two specialized OCT imaging probes to enhance colorectal cancer screening. The $1,471,777 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) aims to create an OCT system that can obtain 3D microscopic images of...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Assistance Listings program CFDA 93.395 Cancer Treatment Research, provides $406,500.00 to support the development of a novel, low-cost, single-use trans-nasal cryotherapy device for esophageal cancer treatment in low-resource settings. The project aims to design and validate a functional prototype of this first-of-its-kind device, which would enable unsedated cryoablation procedures to be administered through...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...
The National Cancer Institute (NCI) awarded a $962,560 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Basic Health International Inc., a non-profit organization in Pittsburgh, Pennsylvania. The grant aims to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries (LMIC). The key goals of the project are to: 1) Modify the IRISTM...
This federal Project Grant award of $718,456 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) supports research and development of an AI-powered system for automated analysis of abdominal CT scans to enhance detection and tracking of metastatic colorectal cancer. The key products and services to be delivered include: 1) Creating a large-scale...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700.00 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at overcoming rapid resistance to targeted therapies in colorectal cancer. The key products and services to be delivered under this 2-year award include: Evaluating how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer through analysis of...
The National Cancer Institute (NCI), under the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $1.2M project grant to Covira Surgical, Inc. to develop a novel phosphate-rich mucoadhesive polyethylene glycol agent, CS-0003, for preventing chemotherapy-related gastrointestinal toxicities and infections in cancer patients. The 1-year project, starting on Sep 18, 2024, aims to demonstrate the safety and efficacy of CS-0003 in ameliorating chemotherapy-induced toxicity and...
This Project Grant award of $405,973 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of Intus Biosciences' TITAN-1 platform as a novel, non-invasive colorectal cancer (CRC) and advanced adenoma (AA) screening tool. The project aims to enhance the TITAN-1 platform's sensitivity and specificity for CRC and AA detection by expanding the machine learning training dataset. Specifically, the research will add approximately 100...
This federal Project Grant award, totaling $592,866, was provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Georgia Tech Research Corporation to develop ingestible nanosensors for the breath-based detection of colorectal cancer. The key objectives of this 5-year project are to engineer ingestible nanosensors that can sense specific enzymes in the intestinal tract associated with colorectal cancer development and release volatile reporter...